TXMD - TherapeuticsMD, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.4650
+0.0050 (+0.20%)
As of 1:09PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close2.4600
Open2.4800
Bid2.4400 x 3100
Ask2.4500 x 800
Day's Range2.3800 - 2.5200
52 Week Range2.2100 - 7.0400
Volume1,854,636
Avg. Volume3,426,554
Market Cap594.612M
Beta (3Y Monthly)2.65
PE Ratio (TTM)N/A
EPS (TTM)-0.6390
Earnings DateNov 1, 2017 - Nov 6, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.83
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents12 days ago

    Edited Transcript of TXMD earnings conference call or presentation 6-May-19 8:30pm GMT

    Q1 2019 TherapeuticsMD Inc Earnings Call

  • Benzinga14 days ago

    Jim Cramer Shares His Thoughts On TherapeuticsMD, Rite Aid And More

    On CNBC's "Mad Money Lightning Round,"  Jim Cramer said he likes Yeti Holdings Inc (NYSE: YETI ) very much. He believes the stock is undervalued and he sees it as a long-time hold. Daktronics, ...

  • Markit15 days ago

    See what the IHS Markit Score report has to say about TherapeuticsMD Inc.

    TherapeuticsMD Inc NASDAQ/NGS:TXMDView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is high * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is extremely high for TXMD with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting TXMD. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, growth of ETFs holding TXMD is favorable, with net inflows of $2.51 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • TherapeuticsMD Enters Agreement to Market Drugs Outside US
    Zacks16 days ago

    TherapeuticsMD Enters Agreement to Market Drugs Outside US

    TherapeuticsMD (TXMD) grants exclusive commercialization rights to its drugs, Bijuva and Imvexxy, to Theramex in ex-U.S. markets except for Canada and Israel.

  • Business Wire16 days ago

    TherapeuticsMD to Host Investor and Analyst Day Today

    TherapeuticsMD, Inc. (TXMD), an innovative, leading women’s healthcare company, will host its Investor and Analyst Day today in New York City. Members of TherapeuticsMD’s management team and key opinion leaders will provide updates on the company’s commercial programs and TherapeuticsMD’s management team will provide financial guidance for 2019. A live webcast and audio archive for the event may be accessed on the home page or from the “Investors & Media” section of the TherapeuticsMD website at www.therapeuticsmd.com.

  • Business Wire19 days ago

    TherapeuticsMD and Theramex Enter into Exclusive License and Supply Agreement to Commercialize BIJUVA™ and IMVEXXY® Outside the United States

    TherapeuticsMD, Inc. (TXMD), an innovative, leading women’s healthcare company, today announced that it has entered into an exclusive license and supply agreement with Theramex, a leading, global specialty pharmaceutical company dedicated to women’s health, to commercialize BIJUVA (estradiol and progesterone capsules) and IMVEXXY (estradiol vaginal inserts) outside of the United States. Theramex is a portfolio company of CVC Capital Partners.

  • Business Wire28 days ago

    TherapeuticsMD to Host Investor and Analyst Day on June 10, 2019 in New York City

    TherapeuticsMD, Inc. (TXMD), an innovative, leading women’s healthcare company, today announced that it will host an Investor and Analyst Day on Monday, June 10, 2019, in New York City. Members of TherapeuticsMD’s management team and key opinion leaders will provide updates on the company’s commercial programs.

  • Business Wire2 months ago

    TherapeuticsMD Announces Participation at the Bank of America Merrill Lynch 2019 Health Care Conference

    TherapeuticsMD, Inc. (TXMD), an innovative, leading women’s healthcare company, today announced that the company will participate in the Bank of America Merrill Lynch 2019 Health Care Conference. Chief Executive Officer Robert G. Finizio will provide an overview of the company at the conference.

  • Here's Why TherapeuticsMD Fell as Much as 17.6% Today
    Motley Fool2 months ago

    Here's Why TherapeuticsMD Fell as Much as 17.6% Today

    The women's health company reported first-quarter 2019 operating results.

  • TherapeuticsMD Inc (TXMD) Q1 2019 Earnings Call Transcript
    Motley Fool2 months ago

    TherapeuticsMD Inc (TXMD) Q1 2019 Earnings Call Transcript

    TXMD earnings call for the period ending March 31, 2019.

  • TherapeuticsMD (TXMD) Reports Q1 Loss, Misses Revenue Estimates
    Zacks2 months ago

    TherapeuticsMD (TXMD) Reports Q1 Loss, Misses Revenue Estimates

    TherapeuticsMD (TXMD) delivered earnings and revenue surprises of 5.88% and -41.61%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    TherapeuticsMD: 1Q Earnings Snapshot

    The Boca Raton, Florida-based company said it had a loss of 16 cents per share. The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...

  • Business Wire2 months ago

    TherapeuticsMD Announces First Quarter 2019 Financial Results

    BIJUVA™ Commercial Launch in April 2019

  • Implied Volatility Surging for TherapeuticsMD (TXMD) Stock Options
    Zacks2 months ago

    Implied Volatility Surging for TherapeuticsMD (TXMD) Stock Options

    Investors need to pay close attention to TherapeuticsMD (TXMD) stock based on the movements in the options market lately.

  • Business Wire2 months ago

    TherapeuticsMD Presented New Research at the American College of Obstetricians and Gynecologists 2019 Annual Meeting that Explores How Women’s Menopausal Symptoms Affect Men

    TherapeuticsMD, Inc. (TXMD), an innovative, leading women's healthcare company, today announced the presentation of results from the Men’s Attitude Toward Menopause Survey (MATE), a large study of men’s understanding of and attitudes related to menopause, at the American College of Obstetricians and Gynecologists 2019 Annual Meeting. The MATE survey showed that while men are sensitive to the changes experienced by women during their menopause transition and believe those changes have a negative impact on their relationships, they are less aware of the specific menopausal symptoms or opportunities available for women to get relief from symptoms. When prompted to select an option, only 55% attributed these symptoms to menopause.

  • Is TherapeuticsMD Inc (TXMD) A Good Stock To Buy?
    Insider Monkey2 months ago

    Is TherapeuticsMD Inc (TXMD) A Good Stock To Buy?

    Legendary investors such as Jeffrey Talpins and Seth Klarman earn enormous amounts of money for themselves and their investors by doing in-depth research on small-cap stocks that big brokerage houses don't publish. Small cap stocks -especially when they are screened well- can generate substantial outperformance versus a boring index fund. That's why we analyze the […]

  • Business Wire2 months ago

    TherapeuticsMD Announces Oral and Poster Presentations on BIJUVA™ and ANNOVERA™ at the American College of Obstetricians and Gynecologists 2019 Annual Meeting

    Poster Will Present BIJUVA Phase 3 REPLENISH Data About Improvements in the Frequency and Severity of Hot Flashes in Postmenopausal Women

  • PR Newswire2 months ago

    SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating TherapeuticsMD, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

    NEW YORK , May 2, 2019 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim ...

  • Business Wire2 months ago

    TherapeuticsMD to Report First Quarter 2019 Results on May 6, 2019

    TherapeuticsMD, Inc. (TXMD), an innovative women’s healthcare company, today announced that it will report its first quarter 2019 financial results on Monday, May 6, 2019, after the closing of the U.S. financial markets. Following the announcement, executive management will host a conference call and webcast at 4:30 p.m. ET on such date to discuss the Company’s financial results and provide a business update.

  • Analysts Estimate TherapeuticsMD (TXMD) to Report a Decline in Earnings: What to Look Out for
    Zacks2 months ago

    Analysts Estimate TherapeuticsMD (TXMD) to Report a Decline in Earnings: What to Look Out for

    TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Business Wire2 months ago

    TherapeuticsMD Closes $300 Million Non-Dilutive Term Loan Financing Facility with TPG Sixth Street Partners

    TherapeuticsMD, Inc. (TXMD), an innovative, leading women’s healthcare company, today announced that it has closed its previously disclosed $300 million non-dilutive secured term loan financing facility with TPG Sixth Street Partners (“TSSP”), the global finance and investment business in strategic partnership with TPG, the global alternative asset firm.

  • Business Wire2 months ago

    TherapeuticsMD Signs Binding Commitment Letter for $300 Million Non-Dilutive Term Loan Financing Facility with TPG Sixth Street Partners

    TherapeuticsMD, Inc. (TXMD), an innovative, leading women’s healthcare company, today announced that it has signed a binding commitment letter for a fully-negotiated $300 million non-dilutive secured term loan financing facility with TPG Sixth Street Partners (“TSSP”), the global finance and investment business in strategic partnership with TPG, the global alternative asset firm.

  • Business Wire2 months ago

    TherapeuticsMD Announces Commercial Availability of BIJUVA™ in the U.S.

    TherapeuticsMD, Inc. (TXMD), an innovative, leading women’s healthcare company, today announced the commercial availability of BIJUVATM (estradiol and progesterone capsules, 1 mg/100 mg) in the United States. BIJUVA is the first and only FDA-approved bio-identical hormone therapy combination of estradiol and progesterone in a single, oral daily capsule for the treatment of moderate-to-severe vasomotor symptoms (commonly known as hot flashes or flushes) due to menopause in women with a uterus.